Leukemia is a life threatening disease that has become increasingly common.
Many categories of anti-leukemic agents have been developed by probing into the
nature of leukemia. Nevertheless, the needs for potent molecules with few side effects
are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been
developed for the advantage of relatively high efficiency and safety in the anticancer
chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases
has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and
Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory
effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain
insight into HDACIs’ potential as anti-leukemic agents.
Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.
Rights & PermissionsPrintExport